Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 3/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | XDH | P47989 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820302 | 0.84 | XDH (0.56) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL5909485 | 0.82 | RAF1 (0.53) | HPGDRAF1MKNK1MKNK2SMN1; SMN2 | |
| SCHEMBL10141691 | 0.81 | KDM4E (0.47) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL19321636 | 0.81 | MEN1 (0.43) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL30281214 | 0.79 | HCAR2 (0.57) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL13384499 | 0.79 | HCAR2 (0.57) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL12728028 | 0.79 | MKNK1 (0.45) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL10141685 | 0.79 | PKM (0.48) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL13466415 | 0.79 | KDM4E (0.48) | GAAMEN1LMNAHPGDKMT2A | |
| SCHEMBL1004004 | 0.79 | HDAC8 (0.43) | HPGDSMN1; SMN2KDM4EALDH1A1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2021213317-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | ARES TRADING S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| US-10357477-B2 | Anticancer compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10208024-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180071258-A1 | ANTICANCER COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-03-15 | — | — | US | disclosed |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | GAA 1279/4885MEN1 1802/4885LMNA 2163/4885 |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | GAA 3859/4885MEN1 645/4885LMNA 2749/4885 |
| US-20180071258-A1 | ANTICANCER COMPOUNDS | RB1, MCL1, TP53 | GAA 1917/4885MEN1 603/4885LMNA 126/4885 |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | GAA 4365/4885MEN1 2521/4885LMNA 4842/4885 |
| US-10208024-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | FGFR1, FGFR2, FGFR3 | GAA 1694/4885MEN1 3903/4885LMNA 3680/4885 |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | GAA 4643/4885MEN1 2298/4885LMNA 4860/4885 |
| US-10357477-B2 | Anticancer compounds | RB1, MCL1, TP53 | GAA 1917/4885MEN1 603/4885LMNA 126/4885 |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR2, FGFR3 | GAA 1694/4885MEN1 3903/4885LMNA 3680/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | GAA 1279/4885MEN1 1802/4885LMNA 2163/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | GAA 1336/4885MEN1 2694/4885LMNA 4258/4885 |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | GAA 4643/4885MEN1 2298/4885LMNA 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.